In:
Cancer Medicine, Wiley, Vol. 5, No. 6 ( 2016-06), p. 1116-1124
Abstract:
Poor prognosis of advanced non‐small‐cell lung cancer ( NSCLC ) patients and the promising therapeutic effect of platinum urge the oncologists to evaluate the role of platinum doublet as second‐line chemotherapy and establish the definition of platinum sensitivity in NSCLC . We retrospectively analyzed 364 advanced NSCLC patients who received platinum‐doublet regimens as second‐line chemotherapy after platinum‐based first‐line treatment. Patients were divided into four groups by their time‐to‐progression ( TTP ) after first‐line chemotherapy: 0–3, 4–6, 7–12, and 〉 12‐month group, respectively. Treatment efficacy of patients' overall survival ( OS ), progression‐free survival ( PFS ), and response rate ( RR ), as well as treatment‐related toxicity, were compared among the four groups. A prognosis score system and a nomogram were established by Cox proportional hazard model, and validated by concordance index (c‐index). Median OS was 14.0, 16.0, 20.0, 25.0 months for patients in the 0–3, 4–6, 7–12, 〉 12‐month group, respectively. Age ≤60 years ( P = 0.002), female ( P = 0.019), and TTP 〉 12 months ( P = 0.003) were independent prognostic factors. Prognostic score was calculated by adding 1 point each for any of the above three indicators, with a c‐index of 0.590 (95% confidential interval [ CI ], 0.552–0.627). Median OS were equal to 25.0, 16.0, and 11.0 months for best (2–3 points), intermediate (1 point) and worst (0 point) category, respectively ( P 〈 0.0001). A nomogram that integrated patient's age, gender, and TTP for OS has a c‐index of 0.623 (95% CI , 0.603–0.643). Female, younger than 60 years, and TTP greater than 12 months may indicate prolonged survival after platinum‐doublet second‐line chemotherapy in advanced NSCLC patients.
Type of Medium:
Online Resource
ISSN:
2045-7634
,
2045-7634
DOI:
10.1002/cam4.2016.5.issue-6
Language:
English
Publisher:
Wiley
Publication Date:
2016
detail.hit.zdb_id:
2659751-2
Permalink